🏥 HCPs: Is this a gap in Sjögren’s disease care? Underrecognition of whole-person burden and lack of individualised multidisciplinary care plans with structured PRO assessment.

🥼 HCPs: Is this a gap in Sjögren’s disease care? Reliance on symptom control and limited familiarity with emerging systemic therapies, including differences in mechanisms, efficacy, and safety.

👩‍⚕️ HCPs: Is this a gap in Sjögren’s disease care? Underuse of ultrasound and biomarkers for earlier diagnosis, alongside a lack of structured approaches to disease stratification.

👋 HCPs: Is this a gap in Sjögren’s disease care? Difficulty recognising SjD as a systemic, B-cell–driven disease with multisystem involvement beyond sicca symptoms.

👋 Calling clinicians who care for children with plaque psoriasis: we'd value your input. Is this a gap in clinical practice? Assessing the full extent and impact of plaque psoriasis affecting skin folds and other sensitive areas in children can be challenging.

🩹 Clinician insights wanted We’re exploring unmet needs in alcohol use disorder in primary care. Is the following a gap in clinical practice? Limited knowledge of, or access to, treatment options for AUD, reducing the incentive to screen

🩺Clinician insights wanted We're exploring glycogen storage disease type Ia (GSDIa). Is the following a gap in clinical practice? Clinicians lack confidence in utilizing genetic testing and diagnostic pathways to support timely diagnosis of GSDIa.

🤝 HCPs, we'd value your perspective We're exploring how specialist cancer care is delivered in everyday practice. Is the following a gap in clinical practice? Coordinating multidisciplinary care and long-term treatment management for patients with ALK-positive lung cancer.

📣Calling all HCPs We’re exploring imaging in early symptomatic Alzheimer’s disease (AD). Is the following a gap in clinical practice? HCPs struggle to interpret PET quantitation and reconcile visual-read discrepancies

🤝 Healthcare professionals: we'd value your perspective. Is this a challenge in practice? Coordinating multidisciplinary care and individualized management for patients with progressing mycosis fungoides and Sézary syndrome.

🩺 HCPs, we'd value your perspective We're exploring preparedness for emerging therapies. Is the following a gap in clinical practice? Applying new evidence and targeted therapies in Juvenile Myasthenia Gravis (JMG), including understanding mechanisms and patient selection.

Welcome to the next instalment in our accredited Epithelioid Sarcoma Quick Bits social learning series. Watch this short reel with Dr Seth Pollack on the role of INI1 loss in diagnosing epithelioid sarcoma. Review evidence-based diagnostic considerations, including: 🔬 INI1 loss as a key clue in suspected ES 🧫 Morphology and broad immunohistochemistry in the differential diagnosis 🧬 When SMARCB1 FISH or NGS may support confirmation 🤝 Integrating pathology, imaging, and multidisciplinary review Please read the CE information and disclosures here before participating in this activity: app.medall.org/articles/es-q… This program is supported by an independent educational grant from Ipsen. This education program is available to healthcare professionals globally. 👉🏽 Get the full series in the link below app.medall.org/articles/es-q…

This is part of our Epithelioid Sarcoma Quick Bits social learning series. Get the full series in the link below. Watch this short reel with Dr Hannah Abrams on treatment sequencing beyond first-line therapy in epithelioid sarcoma. Review evidence-based considerations for later-line ES management, including: 🔄 Sequencing options after progression on first-line therapy 💊 Anthracycline-, gemcitabine-, and pazopanib-based approaches 📊 Real-world response and progression-free survival data 🤝 Individualizing treatment based on subtype, tolerability, quality of life, and patient goals 🏥 Referral to sarcoma-specialized centers and clinical trial consideration Please read the CE information and disclosures here before participating in this activity: app.medall.org/articles/es-q… This program is supported by an independent educational grant from Ipsen. This education program is available to healthcare professionals globally. 👉🏽 Get the full series in the link below app.medall.org/articles/es-q…

Check out the next part of our Epithelioid Sarcoma Quick Bits social learning series. Get the full series in the link below. Watch this short reel with Dr Hannah Abrams on emerging treatment directions in epithelioid sarcoma. Review evidence-based considerations on evolving approaches, including: 🧬 SMARCB1-deficient biology and rationale for targeted strategies 💊 Anti-angiogenic TKI-based combinations in soft-tissue sarcoma 🛡️ Immunotherapy combinations, including checkpoint blockade approaches 📊 Emerging clinical data and investigational strategies relevant to ES 🏥 Clinical trial consideration in this ultra-rare sarcoma Please read the CE information and disclosures here before participating in this activity: app.medall.org/articles/es-q… This program is supported by an independent educational grant from Ipsen. This education program is available to healthcare professionals globally. 👉🏽 Get the full series in the link below app.medall.org/articles/es-q…

This is part of our Epithelioid Sarcoma Quick Bits social learning series. Get the full series in the link below. Watch this short reel with Dr Hannah Abrams on first-line systemic therapy considerations in advanced epithelioid sarcoma. Review evidence-based treatment considerations, including: 💊 Anthracycline-based chemotherapy as a preferred first-line systemic approach 🧬 Classic vs proximal-type ES and implications for treatment discussions 📊 Real-world data on doxorubicin- and gemcitabine-based regimens 🤝 Individualizing therapy based on disease extent, comorbidities, performance status, and patient goals Please read the CE information and disclosures here before participating in this activity: app.medall.org/articles/es-q… This program is supported by an independent educational grant from Ipsen. This education program is available to healthcare professionals globally. 👉🏽 Get the full series in the link below

Welcome to our new, accredited social learning series on Epithelioid Sarcoma: Quick Bits. Watch this short reel with Dr Seth Pollack on early recognition of epithelioid sarcoma. Review evidence-based warning signs that may prompt further evaluation, including: 🔎 Slow-growing, painless soft-tissue nodules 📏 Size, depth, pain, firmness, or progressive enlargement 🩻 MRI features that may raise suspicion 🤝 When to escalate to biopsy and multidisciplinary review Please read the CE information and disclosures here before participating in this activity: app.medall.org/articles/es-q… This program is supported by an independent educational grant from Ipsen. This education program is available to healthcare professionals globally. 👉🏽 Get the full series in the link below

👋HCPs, we'd value your perspective We're exploring understanding of IgAN pathogenesis. Is the following a gap in clinical practice? Understanding the role of B-cell dysregulation and upstream immune mechanisms in the progression of IgAN: